Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia

Christopher B Donahue; Matt G Kushner; Paul D. Thuras; Tom G. Murphy; Joani B. Van Demark; David E. Adson

doi:10.1016/j.janxdis.2008.12.004

Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia

Christopher B Donahue, Matt G Kushner, Paul D. Thuras, Tom G. Murphy, Joani B. Van Demark, David E. Adson

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Objective: Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method: Individuals with SAD (N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result: There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion: Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.

Original language	English (US)
Pages (from-to)	362-368
Number of pages	7
Journal	Journal of Anxiety Disorders
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.janxdis.2008.12.004
State	Published - Apr 2009

Bibliographical note

Funding Information:
This Investigator Sponsored Trial (IRUSQUET0422) was funded in part by a grant from AstraZeneca Pharmaceuticals LP. Clinical Trials Registration: ClinicalTrials.gov identifier NCT00407199 .

Keywords

Public speaking
Quetiapine
Social anxiety
Social phobia
Virtual reality

Access

10.1016/j.janxdis.2008.12.004

OpenUrl availability

Full text

Cite this

@article{43c80fc5dca34657ad89f756978f11f9,

title = "Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia",

abstract = "Objective: Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method: Individuals with SAD (N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result: There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion: Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.",

keywords = "Public speaking, Quetiapine, Social anxiety, Social phobia, Virtual reality",

author = "Donahue, {Christopher B} and Kushner, {Matt G} and Thuras, {Paul D.} and Murphy, {Tom G.} and {Van Demark}, {Joani B.} and Adson, {David E.}",

note = "Funding Information: This Investigator Sponsored Trial (IRUSQUET0422) was funded in part by a grant from AstraZeneca Pharmaceuticals LP. Clinical Trials Registration: ClinicalTrials.gov identifier NCT00407199 . ",

year = "2009",

month = apr,

doi = "10.1016/j.janxdis.2008.12.004",

language = "English (US)",

volume = "23",

pages = "362--368",

journal = "Journal of Anxiety Disorders",

issn = "0887-6185",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia

AU - Donahue, Christopher B

AU - Kushner, Matt G

AU - Thuras, Paul D.

AU - Murphy, Tom G.

AU - Van Demark, Joani B.

AU - Adson, David E.

N1 - Funding Information: This Investigator Sponsored Trial (IRUSQUET0422) was funded in part by a grant from AstraZeneca Pharmaceuticals LP. Clinical Trials Registration: ClinicalTrials.gov identifier NCT00407199 .

PY - 2009/4

Y1 - 2009/4

N2 - Objective: Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method: Individuals with SAD (N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result: There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion: Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.

AB - Objective: Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25 mg) on SAD symptoms. Method: Individuals with SAD (N = 20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1 h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions. Result: There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo. Conclusion: Study findings suggest that a single dose of 25 mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.

KW - Public speaking

KW - Quetiapine

KW - Social anxiety

KW - Social phobia

KW - Virtual reality

UR - http://www.scopus.com/inward/record.url?scp=60749092744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749092744&partnerID=8YFLogxK

U2 - 10.1016/j.janxdis.2008.12.004

DO - 10.1016/j.janxdis.2008.12.004

M3 - Article

C2 - 19157776

AN - SCOPUS:60749092744

SN - 0887-6185

VL - 23

SP - 362

EP - 368

JO - Journal of Anxiety Disorders

JF - Journal of Anxiety Disorders

IS - 3

ER -

Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this